Abstract
TPX-0046 is designed to overcome resistance to FDA approved RET inhibitors Selpercatinib and Pralsetinib. Early prediction of resistance mechanisms to......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
